Keyphrases
Histoplasmosis
100%
Retrospective Cohort
58%
Immune Status
57%
Disseminated Infection
50%
Voriconazole
50%
Itraconazole
50%
Step-down
50%
Immunocompromised Patients
41%
Localized Disease
41%
Azoles
35%
90-day Mortality
33%
People Living with HIV (PLHIV)
33%
Adult Patients
15%
Initial Treatment
14%
Typical Symptoms
8%
HIV Patients
8%
HIV-negative
8%
Radiographic Features
8%
Disease Groups
8%
Large Cohort
8%
Delayed Diagnosis
8%
Immunocompetent Individual
8%
Median Time
8%
Time from Symptom Onset
8%
Lung Nodule
8%
Disease Outcome
8%
Individual Chart
7%
Heaviside Function
7%
Infectious Diseases Society of America
7%
Multivariable
7%
Amphotericin B
7%
Histoplasma Capsulatum
7%
Confidence Interval
7%
Demographic Differences
7%
Cox Proportional Hazards
7%
Single Center
7%
Patient Demographics
7%
Clinical Information
7%
Hazard Ratio
7%
Low Barrier
7%
Increased Mortality
7%
In Vitro Activity
7%
Risk Factors
7%
Barrier Resistance
7%
Clinical Features
7%
Treatment Initiation
7%
Medicine and Dentistry
Histoplasmosis
50%
Disseminated Disease
50%
Immunity
50%
Localized Disease
41%
Human Immunodeficiency Virus
41%
Immunocompromised Patient
25%
Immunity
8%
Lung Nodule
8%
Pharmacology, Toxicology and Pharmaceutical Science
Voriconazole
50%
Itraconazole
50%
Histoplasmosis
50%
Pyrrole
28%
Ajellomyces capsulatus
7%
Amphotericin B
7%
Infection
7%
Clinical Feature
7%
Pyrrole Derivative
7%